Thermo Fisher Scientific (NYSE:TMO – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.
Other equities analysts also recently issued research reports about the stock. BMO Capital Markets downgraded shares of Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Wells Fargo & Company downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a report on Wednesday, September 9th. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 price objective (up from $585.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Finally, Argus boosted their target price on shares of Thermo Fisher Scientific from $560.00 to $780.00 and gave the company a “buy” rating in a report on Friday, October 30th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $683.64.
Check Out Our Latest Stock Analysis on Thermo Fisher Scientific
Thermo Fisher Scientific Stock Down 0.0%
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. The business had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the business posted $5.79 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific will post 25.26 EPS for the current year.
Insider Activity at Thermo Fisher Scientific
In other news, CEO Marc N. Casper sold 275 shares of the company’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $77,707,171.25. This represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 2,831 shares of the stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $706.45, for a total value of $1,999,959.95. Following the completion of the sale, the vice president owned 11,560 shares in the company, valued at $8,166,562. This trade represents a 19.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 24,546 shares of company stock worth $15,479,192 over the last quarter. Corporate insiders own 0.33% of the company’s stock.
Hedge Funds Weigh In On Thermo Fisher Scientific
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legacy Wealth Managment LLC ID boosted its position in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares during the last quarter. Kilter Group LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth approximately $25,000. Allied Private Wealth LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth approximately $26,000. Compass Financial Management LLC raised its stake in Thermo Fisher Scientific by 137.5% in the third quarter. Compass Financial Management LLC now owns 38 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 22 shares in the last quarter. Finally, Pingora Partners LLC purchased a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $30,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.
Key Stories Impacting Thermo Fisher Scientific
Here are a few of the latest stories about TMO:
- Positive Sentiment: A Sound Shore Management investor letter describes Thermo Fisher as near a cyclical bottom, with potential to re-accelerate toward historical growth. That outlook may support sentiment, though it is an investor’s assessment rather than company guidance. Article: Thermo Fisher Scientific cyclical bottom signals re-acceleration
- Neutral Sentiment: CEO Marc Casper is scheduled to join a UBS fireside chat on November 19. Investors may listen for business commentary, but the announcement itself contains no new financial or operational information. Article: UBS CEO Call Series
- Neutral Sentiment: A recent analysis revisits Thermo Fisher’s $5 billion buyback and cash generation after strong multiyear share gains. The buyback supports capital returns, while the discussion highlights the need for future cash flows to justify expectations; the article excerpt gives no new buyback details or firm valuation conclusion. Article: Is Thermo Fisher reasonable after its $5 billion buyback?
About Thermo Fisher Scientific
Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.
Further Reading
- Five stocks we like better than Thermo Fisher Scientific
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
